Cancer predisposition syndromes are typically uncommon, monogenic, high-penetrance disorders. Despite their rarity, they have proven to be highly clinically relevant in directing cancer prevention strategies. As such, they share notable similarities with an expanding class of low-frequency somatic mutations that are associated with a striking prognostic or predictive effect in the tumours in which they occur. In this review, we highlight these commonalities, with particular reference to mutations in the proofreading domain of replicative DNA polymerases. These molecular phenotypes may occur as either germline or somatic events, and in the latter case, have been shown to confer a favourable prognosis and potential increased benefit from immune checkpoint inhibition. We note that incorporation of these variants into clinical management algorithms will help refine patient management, and that this will be further improved by the inclusion of other germline variants, such as those that determine the likelihood of benefit or toxicity from anti-neoplastic therapy. Finally, we propose that such integrated patient and tumour profiling will be essential if we are to deliver truly precision medicine for cancer patients, but in a similar way to rare germline mutations, we must ensure that we identify and utilize rare somatic mutations with strong predictive and prognostic effects.
Introduction
Cancer diagnosis and treatment have advanced hugely during the last few decades. However, for most common solid tumours, surgical and medical management still tends towards a one-size-fits-all approach within broad strata defined by clinicopathological and, in a few cases, molecular risk factors. The development and clinical application of technologies such as next-generation sequencing (NGS) provide an opportunity to move beyond this paradigm towards a more personalized model of cancer care. In particular, NGS has vastly increased the capacity for both the discovery and the clinical detection of two classes of genetic variants central to the delivery of precision cancer medicine: the first are germline variants causative of cancer predisposition syndromes; the second are somatic driver mutations in tumours. Incorporating both types of variants into clinical management algorithms is no small task, but it will be essential to transforming the 'one-size-fits-all' approach into patient-tailored, genomics-driven cancer therapeutics.
In this review, we note that, in many ways, cancer predisposition syndromes exemplify the concept of 'precision' cancer medicine. Identifying patients who possess the underlying germline genetic variants, a form of 'biomarker', allows for the prescription of specific preventative interventions and counselling about long-term cancer risk. Furthermore, in the event that these patients do develop cancer, our understanding of the genetic mechanisms of oncogenesis permits tailoring of treatment regimens in several cases, such as the use of PARP inhibitors in carriers of BRCA1/2 mutations [1] . Building on these observations, we highlight the similarities between the management of patients with such germline variants and those whose tumours harbour rare somatic variants with large effects, with reference to our recent studies of mutations in the proofreading domain of replicative DNA polymerases. We note that treatment can be further refined by the incorporation of uncommon germline variants that [72, 73] substantially alter the chances of benefit or risk of toxicity from systemic anti-cancer therapy. Finally, we discuss how these factors can be integrated to deliver truly precision medicine, with particular reference to colorectal cancer (CRC), but also drawing on examples from other malignancies where relevant. In a few cases, germline mutations at the extreme ends of the APC gene and in exon 9 cause an attenuated form of the disease, with tens of polyps that can often be managed using regular colonoscopy alone. A further variant of FAP has recently been recognized; known as gastric adenomatous and proximal polyposis of the stomach (GAPPS) syndrome, it is the result of point mutations in the APC promoter 1B. GAPPS sufferers develop polyposis of the gastric body and fundus, but not of the colon, and there is no apparent associated increased risk of CRC [6, 7] . Although these genotype-phenotype correlations are not perfect, and unknown factors also affect the severity of colonic polyposis in FAP, they can be used as a means of choosing first-line cancer preventive treatment. The underlying cause for these correlations is probably that many truncated APC proteins are stable and retain some function, affecting the extent to which they activate Wnt pathway signalling and hence promote tumourigenesis. Lynch syndrome (LS) is the commonest Mendelian predisposition to CRC, accounting for around 3% of all cases. LS is caused by inherited defects in DNA mismatch repair -a cellular process, responsible for correcting base-base mismatches and insertion-deletion loops following DNA replication [8] . LS is inherited in an autosomal dominant fashion, and sufferers are at greatly increased risk of CRC and endometrial cancer (EC), and at a lesser increased risk of several other cancer types [9] . Colorectal polyp numbers are not greatly increased in LS, and most patients are managed by regular colonoscopy, although both prophylactic surgery and chemoprevention are also offered. LS is caused by germline mutations in one of four genes encoding mismatch repair (MMR) proteins: MSH2 [10] , MLH1 [11, 12] , PMS2 [13] , and MSH6 [14] . Additionally, LS can be caused by inherited mutations at the 3' end of the EPCAM gene, which leads to hypermethylation and epigenetic silencing of MSH2 [15] . Genotype-phenotype correlations, including reduced penetrance of MSH6 and PMS2 mutations, have been reported, but few are strong enough to use in clinical practice. Loss of MMR function following a 'second hit' causes a hypermutated state, with a 10-to 100-fold increased mutation rate in cancers, and a particular increase of small insertion and deletion mutations at DNA microsatellites, a phenomenon known as microsatellite instability (MSI) [16, 17] . MMR deficiency also occurs in sporadic tumours (∼15% of CRCs and ECs), most commonly because of somatic transcriptional silencing of MLH1 ( Figure 1 ) [18, 19] . Recent reports have also highlighted the existence of a small proportion (∼4%) of MSI tumours that have been coined as 'double somatic', a term that refers to cancers that harbour biallelic somatic mutations in MMR genes in patients who lack germline MMR gene mutations [20] . The MMR status of CRC is important, because it is the most rigorously validated molecular prognostic biomarker currently available to clinicians. Both a meta-analysis and several large clinical trials have demonstrated that MMR deficiency is associated with a significantly better prognosis in stage II disease, with a risk of recurrence roughly half that of MMR-proficient cancers [21] [22] [23] . Furthermore, exciting recent data demonstrate that MMR-deficient (MMR-D) cancers respond particularly well to immune checkpoint inhibition therapy [24] . Thus, identification of LS patients may allow for the implementation of a focused preventative strategy and, in the eventuality of malignancy developing, a specific treatment strategy.
Management of patients with high-penetrance germline predisposition variants for colorectal cancer (CRC)
Unlike APC and MLH1, the genes mutated in most of the Mendelian CRC syndromes play no clear role in sporadic CRC. One exception is SMAD4, which is mutated in the germline of patients with juvenile polyposis and in ∼10% of sporadic CRCs [25] ; another is POLE, which encodes the major subunit of the leading strand DNA polymerase Pol ε. The equivalent subunit of the lagging strand polymerase Pol δ is encoded by POLD1. Both of these proteins contain a polymerase domain, which extends the primer strand by addition of bases opposite the template strand, and an exonuclease domain, which functions to proofread the newly synthesized DNA as replication proceeds [26, 27] . On the (uncommon) occasion that an incorrect base is incorporated by the polymerase, a conformational alteration results in pausing of the replication complex, and excision of the mispair through a reaction catalysed by the highly conserved active site residues that lie within the exonuclease domain Exo motifs. Following this, the correct base is inserted, and DNA replication may continue. Polymerase proofreading is essential for accurate DNA replication, and amino acid substitutions within the exonuclease domain active site residues increase the mutation rate approximately 100-fold ( Figure 1 ) [28] . Germline missense mutations in the exonuclease domains of POLE and POLD1 disrupt polymerase proofreading and predispose to polyposis, early-onset CRC, and EC [29] . The syndrome was named polymerase proofreading-associated polyposis or PPAP [30] .
POLE proofreading domain mutations are also somatic events in sporadic cancers, occurring in around 3% of CRCs [18] and 10% ECs [19, 31] . The POLE-mutant cancers are termed 'ultramutated', as they harbour up to 1 000 000 detectable base substitutions, a burden which far exceeds that of MMR-D cancers [18, 19, 26, 32] . The most common somatic POLE mutation in sporadic tumours is a p.Pro286Arg substitution flanking the Exo I motif, and other recurrent mutations include p.Val411Leu, p.Ser297Phe, and p.Ser459Phe alterations [26] . These findings have now been confirmed in multiple different colorectal and endometrial cancer cohorts [18, 19, [31] [32] [33] [34] [35] [36] , and pathogenic POLE exonuclease domain mutations have also been reported in highly mutated tumours of the brain [37] , stomach [38] , breast, and pancreas (cBioPortal, http://www .cbioportal.org/; accessed 3 October 2016). Strikingly, very few clearly pathogenic somatic POLD1 exonuclease domain mutations have been detected, despite the fact that several hundred cases of most common tumour types have now been sequenced [26] . Consequently, it appears that if somatic POLD1 mutations do occur in sporadic cancers, they do so with a prevalence that is less than 1% of cases. Although very intriguing, the reason for this discordance with the germline is unclear.
In addition to their exceptional mutational load, tumours with pathogenic POLE exonuclease domain mutations also display a distinctive mutation spectrum, with a pattern of base substitutions and a striking relative increase in C > A transversions in the context of TCT trinucleotides [31, 32, 39] . In addition, the specific driver mutations found in POLE-mutant tumours differ somewhat from the majority of sporadic CRCs or ECs. The overrepresented changes in CRCs include APC p.Arg1114*, TP53 p.Arg213*, and KRAS p.Ala146Thr.
Similar phenomena occur in POLE-mutant ECs, and these cancers also tend to acquire inactivating APC changes rather than oncogenic CTNNB1 mutations as a means of activating the Wnt pathway. This combination of features means that these POLE-mutant tumours are often identifiable using next-generation sequencing panels in clinical use in academic centres [40] . This distinct tumour mutational signature may also help to identify patients who carry germline POLE mutations.
Endometrial cancers with somatic POLE mutations have a favourable prognosis, with a risk of relapse between one-third and one-tenth of that of other ECs, depending on risk stratum [35, 36, [41] [42] [43] . We have recently shown that CRCs with pathogenic POLE exonuclease domain mutations have a similarly good prognosis, which appears superior to that of MMR-D CRCs [44] . In both tumour types, this may relate to a 230 MA Glaire et al strong immune response against these cancers, as evidenced by immunohistochemical analysis for the T-cell markers CD8 and CD3, and increased expression of cytotoxic T-cell genes in RNA from non-microdissected whole tumours [44] [45] [46] . Perhaps unsurprisingly, in view of their ultramutation, bioinformatic analysis has confirmed that POLE-mutant tumours are predicted to harbour a substantially greater number of neo-epitopes (that is, mutations capable of eliciting an immune response) than other tumours [45] [46] [47] , a feature that may account for their apparently enhanced immunogenicity. Both increased neo-epitope burden and a pretreatment lymphocytic infiltrate appear to predict benefit from immune checkpoint inhibition [48, 49] , and consistent with this, very recent studies have reported complete response of POLE-mutant endometrial cancers to these agents [45, 50] . The efficacy of immune checkpoint inhibitors against POLE-mutant tumours along with hypermutated MMR-D cancers will be investigated by several prospective clinical trials currently recruiting or in set-up.
An unresolved issue is whether the management of cancers in Mendelian syndromes should follow that of sporadic cancers where the same gene is involved. Clearly, this is problematic, because the rarity of the Mendelian syndromes means that standard methods for answering this question, such as randomized controlled trials, are infeasible. In the absence of such data, it is tempting to use similar therapeutic strategies for MMR-D cancer in the sporadic and LS settings, and also to treat sporadic and PPAP POLE-ultramutated cancers in the same way. In both cases, however, there are clear differences between sporadic and inherited disease. For example, sporadic MMR-D CRCs tend to occur in older individuals and women, and are almost all in the proximal colon, whereas LS CRCs can present from the late teens onwards, are more prevalent in men, and are often in the distal colon or rectum. Given that recent studies have suggested substantial variation in the impact of MMR deficiency depending on tumour location (proximal versus distal colon) [51] , it will be important to define the impact of these differences on tumour biology and management. Such efforts will require large-scale collaboration between multiple investigators.
Although challenging, the management of rare subgroups such as patients with Mendelian cancer syndromes or rare (but well-defined) subgroups of sporadic cancers (e.g. POLE-mutant CRCs) will be central to the promised era of precision medicine.
The uncertain future of precision cancer medicine
Somatic POLE mutations occur in a modest fraction of endometrial cancers, a smaller proportion of colorectal cancers, and at a very low frequency in all other tumours in which they have been found; pathogenic germline POLE and POLD1 mutations are probably present in fewer than 1 in 1000 people. Yet as discussed in the preceding section, the apparent effect of POLE on tumour prognosis and, potentially, on therapeutic response is striking. We contend that in the light of these characteristics, POLE-mutant tumours highlight the challenges posed in delivering personalized or precision medicine in the genomic era, because true precision requires the identification of clinically important patient subsets that comprise at most a few per cent of the total. Examples of clinically relevant, low-frequency biomarkers with predictive or prognostic value are shown in Table 2 .
For most of the common cancers, the number of tumours sequenced to date is such that essentially all mutations that occur in more than 20% of cases have already been discovered. In fact, many of these mutations, such as TP53, APC, and KRAS, were already known well before the use of NGS became widespread in the latter part of the last decade. As the number of cancers analysed continues to grow, so the mutation prevalence of any novel driver genes discovered will tend to decrease in parallel, reflecting the greater power to detect these variants provided by the larger number of cases. Indeed, an elegant study published in 2014 demonstrated that the number of modest frequency (5-10% cases) drivers was increasing linearly and that of low frequency (2-5% cases) drivers was increasing in a log-linear fashion [52] . This profusion of mutations with possible prognostic and predictive utility raises challenging questions for the research community. For example, consider a candidate biomarker present in 1% of cases, which confers risk of recurrence one-third that of biomarker-negative cases, for which the risk of recurrence is 20%. In the absence of confounding from other clinical or pathological factors, confirming this effect with conventional levels of type I and II error (two-sided α of 0.05 and 1 − β of 0.8) requires a total of 3226 cases. Clearly, this is a major undertaking that requires the analysis of a greater number of cases than are available in all but the largest of clinical trials. In our recent study of POLE mutations in colorectal cancer, we analysed three large clinical trial sample sets and several additional large sample biobanks, comprising more than 4500 CRC cases in all, to confirm the prognostic effect [44] .
Determining that low-frequency biomarkers have a predictive effect poses additional, particular challenges. Screening large numbers of people to detect a small fraction of biomarker-positive cases is costly and inefficient, and means that many patients face disappointment when they are unable to participate in the study. Though logistically demanding, perhaps the best solution to this problem will be to embed treatment of low-frequency biomarker groups within the context of a larger precision medicine trial, where patients are allocated to a particular therapy tailored to their tumour molecular profile [53] . This, of course, could reasonably be allocation to no additional treatment after surgery in the case of markers of favourable prognosis.
While NGS promises the potential for significant advances in cancer medicine, at least in part through the identification of novel biomarkers, we suggest a note of caution. There is a danger that the careless 
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Colorectal cancer (5%) [75] ALK ALK rearrangements identify patients with advanced non-small cell lung cancer that may benefit from crizotinib therapy Non-small cell lung cancer (3-5%) [76] application of these technologies will not only fail to benefit patients with sporadic cancers, but may even cause harm as a consequence of abandoning the principles of evidence-based practice. There are no simple solutions to this problem. As we note above, adherence to a frequentist statistical approach means that, for rare somatic biomarkers, large sample sizes are required to detect all but substantial effect sizes. Bayesian approaches offer some advantages in this regard, but are often criticized for the subjectivity of assigning prior probabilities, based on assumptions that may be quite mistaken. For example, the impressive responses of melanomas to specific inhibitors of the mutant BRAF kinase might have suggested that these agents would demonstrate similar efficacy in other tumour types with this mutation. In fact, the effect of these drugs against BRAF-mutant CRCs was essentially negligible, due to compensatory up-regulation of EGFR signalling. We contend that the use of such priors should not be completely abandoned, but rather used with caution when translating results between different cancer types. The question remains as to whether we will ever be able to provide currently accepted levels of proof for some well-defined patient subgroups. For example, even for LS, let alone PPAP, a phase 3 clinical trial of immune checkpoint inhibitors is currently unthinkable even though LS is claimed to account for ∼3% of CRCs. Whether patient registries, international collaborations, and alternative statistical methods, for example, propensity score matching, can deal with these issues requires careful evaluation. If not, there is a very real risk that what is termed 'precision medicine' will in fact be a return to the bad old days of patient care based on small case reports -a model subject to multiple confounders, biases, and well recognized as being fundamentally unsound. The Exceptional Responders Initiative coordinated by the National Cancer Institute is approaching this issue in a reverse manner by attempting to define the molecular characteristics of small patient subsets that exhibit remarkable responses to cancer therapies. It remains to be seen whether the results of this study, which is focusing on groups of 'outliers', can be generalized to a wider patient population [54, 55] .
Intersection between germline and somatic variants in precision medicine
The previous sections have highlighted the clinical relevance of low-frequency genetic variants in both the germline and the soma in clinical practice. We propose that to work towards truly precision medicine, clinical management algorithms must incorporate both classes of alteration. In the case of germline variants, these are not only limited to those that predispose to cancer, but may also include those that influence response to treatment or therapeutic toxicity. Examples of such germline variants that may predict toxicity are described in Table 3 [56] [57] [58] [59] . For example, a woman presents with a stage III colorectal cancer that displays a prominent lymphocytic infiltrate, but is found to retain expression of mismatch repair protein expression on IHC. Molecular testing confirms that her tumour harbours a somatic POLE p.Pro286Arg mutation. Although the prognosis for these tumours appears somewhat better than that of MMR-P cancers of similar stage that lack POLE mutations, current evidence is insufficient to recommend omission of adjuvant chemotherapy. The patient is considered for a clinical trial of chemotherapy with an immune checkpoint inhibitor, but declines this and instead opts for standard post-operative treatment with oxaliplatin and the oral fluoropyrimidine capecitabine. However, genetic testing reveals that she carries a rare loss-of-function DPYD*2A allele, meaning that standard-dose capecitabine treatment would probably cause substantial toxicity [60] . In keeping with recent reports and emerging consensus [61] , she is therefore treated with capecitabine at 50% dose, at which it is well tolerated.
While this illustrative case is taken from the field of colorectal cancer, there are similar examples in many other tumour types, where both germline and somatic mutation testing have the potential to improve patient care from the point of diagnosis through to individualized treatment (Figure 2) . Frustratingly, however, although in many cases the evidence supporting such testing is clear and unequivocal, clinical practice has lagged behind, as illustrated by the patchy implementation of MMR testing for colorectal cancers in UK practice.
The 100,000 Genomes Project, launched in the UK in 2012, is a government-funded project that aims to sequence 100 000 genomes from patients with cancer (or rare genetic diseases), recruited from within the National Health Service (NHS). In addition to providing a wealth of data, this project also represents an important step in fully integrating genomic research with routine clinical practice [62, 63] .
Conclusions
In the last 5 years, NGS has hugely increased our understanding of cancer genomes. As we have highlighted in this review, the application of NGS has also helped to identify an increasing number of rare somatic variants of potential value as biomarkers. Translating these discoveries into clinical practice poses a considerable challenge, but will be central to the implementation of precision cancer medicine. We contend that consideration of the clinical management of germline cancer predisposition variants provides some clues as to how this may be achieved. The same principles of detailed consideration of the pathogenicity of mutations, careful documentation of any prognostic or predictive effect of the variant (through a randomized controlled clinical trial where appropriate), and the rapid dissemination of this through evidence-based consensus guidelines all apply to the study of rare somatic variants. Other parallels can be drawn from phenotypes associated with germline variants that display lower penetrance, such as prostate cancer BRCA2 mutation carriers. The challenge faced in confirming this association is similar to that we face when considering the many biomarkers with a more modest effect. Understanding the effect of these both alone and in combination will require large-scale collaborative working, meticulous data collection, and rigorous statistical analysis.
During the last two decades, advances in the diagnosis and clinical management of patients with rare, high-penetrance, germline tumour-predisposition variants have substantially reduced morbidity and mortality from cancer [64, 65] . Applying similar principles to the rapidly expanding number of rare somatic mutations in common cancers is essential if we are to realize the benefits that NGS offers, and move towards the goal of truly precision medicine for cancer patients.
